“It’s important to be both an encourager and a critic, asking the right questions and setting challenging goals, to move new therapies into broad clinical practice.”

Homer L. Pearce, PhD


After training as a synthetic organic chemist, Dr. Homer Pearce served for 27-years at Eli Lilly and Co. in the areas of cancer drug discovery and clinical development.  As Lilly’s oncology presence grew, Dr. Pearce held several positions of increasing responsibility. He served as Vice President of Cancer Research and Clinical Investigation and became a Distinguished Research Fellow, Cancer Research. During this time Lilly’s cancer drug discovery group introduced 25 investigational drugs into clinical trials and 3 new drugs were approved for the treatment of cancer by worldwide regulatory agencies including Gemzar and ALIMTA. Dr. Pearce retired from Lilly in 2006, and has served in several board, consulting, and advisory roles in the academic, government and biopharmaceutical communities.  Homer Pearce received a BS degree in chemistry from Texas A&M University in 1974 and was awarded a PhD in organic chemistry from Harvard University in 1979.  In 2006 he was named a “Hero of Chemistry” by the American Chemical Society.  Dr. Pearce delights in helping to move new medicines from the laboratory into the clinical trial process and seeing new standards of care emerge from successful drug discovery enterprises.